Sanofi Consumer Healthcare India Limited (SANOFICONR) Q3 2026 earnings summary

Executive summary

• Q3’26 revenue from operations was ₹2,631 million, up 12% YoY; PBT was ₹1,027 million, up 22% YoY.

• Nine-month revenue was ₹7,280 million, up 16% YoY, and PBT increased 24% YoY.

Financial highlights

• Q3’26 profit for the period was ₹766 million versus ₹629 million in Q3’25; nine-month profit was ₹2,132 million versus ₹1,736 million.

• Q3’26 total income was ₹2,675 million versus ₹2,369 million YoY; nine-month total income was ₹7,443 million versus ₹6,412 million.

• Product sales were ₹2,438 million in Q3’26 versus ₹2,132 million YoY; nine-month product sales were ₹6,634 million versus ₹5,715 million.

Segment performance

• Operations are reported as one business segment, Pharmaceutical Business.

• Domestic sales grew 19% in Q3’26 and 15% in 9M’26; nine-month domestic growth was aided by product relaunches.

• Export sales grew 19% in 9M’26.